Effect of Reactive Balance Training Versus Conventional Balance Training on Dynamic Stability and Change-of-Direction Performance in Competitive Tennis Players

June 23, 2026 updated by: Hafsah Gul Khattak, Ibadat International University, Islamabad
This randomized controlled trial aims to compare the effectiveness of reactive balance training versus conventional balance training on dynamic stability and change of direction performance. Participants will be randomly allocated into two groups. Each group will receive its respective intervention over a 6-week period. Outcome measures, including dynamic stability assessed by the Y-Balance Test and change-of-direction performance measured using the 505 Agility Test, will be evaluated at baseline and after the intervention. The study is designed to determine which training approach is more effective in improving balance and functional performance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a randomized controlled trial comparing two balance training interventions in competitive tennis players. Participants will be randomly assigned to either a reactive balance training group or a conventional balance training group. Both groups will undergo a supervised training program for 6 weeks, with three sessions per week. Each session will include a warm-up, a structured balance training program, and a cool-down phase. The reactive balance training group will perform exercises involving external perturbations, unpredictable stimuli, and sport-specific reactive movements such as sudden directional changes, partner-induced disturbances, and dual-task activities. The conventional balance training group will perform static and controlled balance exercises, including single-leg stance, balance board activities, and slow, predictable movements without external perturbations. Training intensity and duration will be standardized across both groups. Pre- and post-intervention assessments will be conducted to evaluate changes in dynamic stability and change-of-direction performance.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
64

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Laiba Zia Laiba Zia, DPT, MSPT (SPORTS)
  • Phone Number: +92923125299816
  • Email: zialaiba0@gmail.com

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male and female competitive tennis players aged 18-25 years.
  • Minimum 2 years of regular tennis training experience.
  • Currently training at least 3 sessions per week (minimum 60 minutes per session).

Exclusion Criteria:

  • Recent injury (last 3 months)
  • Neurological, balance or vestibular disorders
  • Previous surgery
  • Participation in any structured balance, neuromuscular, plyometric, or agility training program outside regular tennis practice during the study period.
  • Use of ankle/knee braces or orthotic devices that may influence balance performance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Reactive balance training
Participants in this group will receive a structured reactive balance training program focusing on unpredictable, perturbation-based exercises to enhance neuromuscular control and dynamic stability. The intervention will include single-leg stance with manual perturbations, reactive stepping, sudden directional changes in response to verbal or visual cues, resistance band perturbations, and tennis-specific reactive movements. Exercises will be progressively advanced by increasing instability, speed of response, and dual-task demands.
Other: Experimental group : Reactive Balance Training
Participants will receive a structured reactive balance training program based on unpredictable perturbation-based exercises requiring rapid postural correction. The intervention will be conducted for 6 weeks (3 sessions/week) and will follow a progressive protocol.
Active Comparator: Conventional Balance Training
Participants in this group will receive a structured conventional balance training program focusing on static and controlled balance exercises without external perturbations.
Other: Active comparator ( Conventional Balance Training)
Participants will receive a structured conventional balance training program based on static and controlled exercises without external perturbation, conducted for 6 weeks (3 sessions/week).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Dynamic Stability
Time Frame: Baseline (Pre-intervention) and after 6 weeks (Post-intervention)
Dynamic stability will be assessed using the Y-Balance Test (Lower Quarter), which measures reach distance in anterior, posteromedial, and posterolateral directions. The composite score (normalized to limb length) will be used to evaluate postural control and balance performance.
Baseline (Pre-intervention) and after 6 weeks (Post-intervention)
Change of Direction Performance
Time Frame: Baseline (Pre-intervention) and after 6 weeks (Post-intervention)
Change-of-direction ability will be assessed using the 505 Agility Test, which measures the time (in seconds) required to accelerate, change direction (180° turn), and return over a set distance. Lower time indicates better performance.
Baseline (Pre-intervention) and after 6 weeks (Post-intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ibadat International University, Islamabad

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Hafsah Gul Khattak, DPT, MSNMPT, Ibadat International University, Islamabad (Iiui)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 12, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 15, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 26, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 23, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IIUI/RERC/ADT/2026/04/284

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings